



SINAPPS

Welcome to our first newsletter issue


Through our monthly newsletters we plan to keep you up to date with the latest news from the PPI2 and SINAPPS2 studies. We will also be happy to include short contributions from our research friends and colleagues so please do send us anything you would like to be included.

SINAPPS group studies overview



PPI1 Study (2013-2014)
14-35 years of age
First episode of psychosis
Antipsychotic medication < 6 weeks

PPI2 Study (2015 – 2020)
18-70 years of age
First episode of psychosis or relapse



SINAPPS

SINAPPS-1 (2015-2017)
Feasibility Study
Immunotherapy in antibody positive patients

SINAPPS-2 (2017- 2021)
Clinical Trial
IVIg and Rituximab vs. placebo in antibody positive patients


2013 2014 2015 2016 2017 2018 2019 2020 2021

PPiP-2 updates

PPiP2 continues to expand! We have just recently opened new sites in London (Camden and Islington & Barnet and Enfield and Haringey) and in Kent and Medway. Recruitment is conducted in 30 sites across England. Other trusts around the country are also showing an interest in being part of PPiP2. We will keep you informed of our progress.

As you can see from the graph, PPiP2 recruitment has improved dramatically over the last 6 months. We would like to thank all of you for this accomplishment and wish you all the best with your continued contribution to the study.

Cumulative Recruitment for PPiP2 January 2015 – April 2017



SINAPPS-2 updates

The first SINAPPS sites in Oxford, Cambridge and London will be up and running in July. So if you recently had positive PPI2 participants at your sites we will get in touch with you soon! Keeping the PPI2 recruitment figures high is vital for the success of the SINAPPS2 trial. We can recruit enough participants only if we identify enough PPI2 participants with anti-neuronal membrane antibodies.



Meet the PPI2 management team

We are now much bigger team than last year. From right: The head of our team is Professor Belinda Lennox, Clinical Senior Lecturer, Honorary Consultant Psychiatrist and Clinical Director NIHR CRN: TV&SM. The team in Oxford was expanded this year with our energetic new SINAPPS2/PPI2 Research Assistants from Oxford Health NHS Foundation Trust: Rosa Ritunnano (Birmingham), Giuliano Tomei (Cambridge). Jane Hainsworth, PPI2 Research Coordinator, Sally-Anne Vincent, Research Assistant and Ksenija Yeeles, SINAPPS Project Manager (PPI2, SINAPPS1 and SINAPPS2) are located at the Department of Psychiatry, University of Oxford. And finally, Rebecca Pollard, Research Assistant is based in London.

PPI2 recruitment

We are absolutely delighted to announce that the teams in **Nottingham, Oxford, Cambridge, Avon and Wiltshire, Oxleas and South West London continue to be our best recruiting sites. Well done!** All of these sites already hit their recruitment target for September 2017 and they keep recruiting! A special mention for the team in **Norfolk & Suffolk**, as they are just a few patients away from hitting their yearly target. Thank you for your continued effort and commitment!

In each issue of our Newsletter we will introduce the best recruiting PPI2 site of the previous month. It is not too late to become the best one in June! We hope all sites will be mentioned in this section during the PPI2 study period.

Media coverage of antibody research

There is now a great deal of interest in the association between antibodies and their link to mental illness, specifically psychosis. Belinda has appeared on BBC Radio 4 and also on television talking about this. See links below.

[“The Inflamed Mind” radio interview](#)

[BBC Health on antibodies in psychosis](#)

[“Antibodies that may be the cause of schizophrenia in some patients”](#)

CONTACTS

London: rebecca.pollard@psych.ox.ac.uk

East of England: giuliano.tomei@psych.ox.ac.uk

Midlands: rosa.ritunnano@psych.ox.ac.uk

South West : sally-anne.vincent@psych.ox.ac.uk

Project management: ksenija.yeeles@psych.ox.ac.uk